

Ref No.: ZLL/CS/BM/BSE-NSE

Date: 06.08.2026

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--	---

Dear Sir,

Sub : Outcome of Board Meeting held on 06.08.2026

Ref : Notice of Board Meeting dt. 31.07.2026

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, 06th August, 2026 have inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026.

Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith.

Kindly take the intimation on record.

The Board Meeting commenced at 10:30 a.m. (IST) and concluded at 01:50 p.m. (IST)

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl: as above

ZIM LABORATORIES LIMITED

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **ZIM LABORATORIES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the following entities:

Name of the Company	Relationship
ZIM Laboratories Limited, India	Parent Company
ZIM Laboratories FZE, Sharjah	Subsidiary Company
ZIM Health Technologies Limited, India	Subsidiary Company
SIA ZIM Laboratories Limited, Latvia	Subsidiary Company
ZIM Thinorals Private Limited, India	Subsidiary Company
ZIMTAS PTY Limited, Australia	Subsidiary Company
ZIM Scientific Office LLC, Dubai	Step-Down Subsidiary

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

**VIRAL
RAJNIKAN
T SHAH**

Digitally signed by
VIRAL RAJNIKAN
SHAH
Date: 2026.08.06
13:13:30 +05'30'

Viral R. Shah
Partner

(Membership No.117654)
(UDIN: 26117654YSGOIG3110)

Place: Mumbai
Date: 06 August 2026



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India

CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Unaudited) Refer Note 3	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	9,417.85	10,527.34	7,175.61	37,440.01
	b) Other income	99.23	616.21	147.63	1,138.30
	Total income	9,517.08	11,143.55	7,323.24	38,578.31
2	Expenses				
	a) Cost of materials consumed	4,381.61	4,970.37	2,761.73	16,404.76
	b) Purchases of stock-in-trade	50.91	235.96	159.30	746.83
	c) Changes in inventories of finished goods and work-in-progress	(485.87)	(493.83)	79.86	(614.14)
	d) Employee benefits	1,918.37	1,739.15	1,461.27	6,390.38
	e) Finance costs	364.34	331.03	330.35	1,320.23
	f) Depreciation and amortisation	537.22	510.29	486.35	1,997.80
	g) Other expenses	3,307.80	3,356.41	2,287.58	11,511.17
	Total expenses	10,074.38	10,649.38	7,566.44	37,757.03
3	Profit /(loss) before tax (1-2)	(557.30)	494.17	(243.20)	821.28
4	Tax expense /(credit)				
	Current Tax	0.02	181.78	8.72	342.39
	Deferred Tax	(155.62)	(61.60)	(64.43)	(104.92)
	Total tax expense /(credit)	(155.60)	120.18	(55.71)	237.47
5	Net Profit /(loss) after tax (3-4)	(401.70)	373.99	(187.49)	583.81
6	Other comprehensive income				
	a) Items that will not be reclassified to profit or loss	(3.46)	43.12	(18.99)	(13.85)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	1.01	(12.56)	5.53	4.03
	c) Items that may be reclassified to profit or loss	39.40	19.07	55.35	220.49
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-
	Other comprehensive income (net of tax)	36.95	49.63	41.89	210.67
7	Total comprehensive income /(loss) (5+6)	(364.75)	423.62	(145.60)	794.48
8	Net Profit /(loss) after tax attributable to				
	Owners	(401.68)	373.98	(187.49)	583.81
	Non-controlling interest	(0.02)	0.01	-	-
9	Other comprehensive income attributable to				
	Owners	36.95	49.63	41.89	210.67
	Non-controlling interest	-	-	-	-
10	Total comprehensive income /(loss) attributable to				
	Owners	(364.73)	423.61	(145.60)	794.48
	Non-controlling interest	(0.02)	0.01	-	-
11	Paid-up equity share capital (face value of Rs. 10/- each)	5,354.90	5,350.03	4,872.58	5,350.03
12	Other equity (revaluation reserve : Rs. Nil)				24,265.33
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)				
	Basic	(0.75)	0.76	(0.38)	1.19
	Diluted	(0.75)	0.76	(0.38)	1.19

RB

Notes :

1) The above statement of consolidated financial results of ZIM Laboratories Limited ('the Parent' or 'the Company') and its subsidiaries (together referred to as 'Group') were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 August 2026 and 06 August 2026. The above results have been subjected to limited review by Statutory Auditor of the Company.

2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the year ended 31 March 2026 and year to date figures upto 31 December 2025, on which auditors had performed a limited review.

4) The Group is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 06 August 2026

RB

**Anwar
Siraj Daud**

Anwar S. Daud
Managing Director

Digitally signed by Anwar Siraj Daud
DN: c=IN, o=Personal, postalCode=440002, l=Nagpur,
st=Maharashtra, street=opposite husamrao high school
Shanti nagar, Nagpur City H.O, Maharashtra India 440002
daud compound, title=9918,
2.5.4.20=511c23a9503d9ee0 12317cb9fed81e7e0f60a9b9
b0675b76c0e2e6c67f5a92,
serialNumber=f3c3d2b1c8ef6d1f85c8f3f8e73ebbc5ddc
a31586ca7c8873126c2a61e6dc,
email=Anwar.daud@zimlabs.in, cn=Anwar Siraj Daud
Date: 2026.08.06 12:02:24 +05'30'

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **ZIM LABORATORIES LIMITED** ("the Company"), for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

VIRAL
RAJNIKA
NT SHAH
Digitally signed
by VIRAL
RAJNIKANT SHAH
Date: 2026.08.06
13:12:55 +05'30'

Viral R. Shah
Partner
(Membership No. 117654)
(UDIN: 26117654WWNWDA6750)

Place: Mumbai
Date: 06 August 2026

RB



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Year ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Unaudited) Refer Note 3	(Unaudited)	(Audited)
1	Income				
	a) Revenue from operations	9,304.83	10,285.37	7,142.77	37,048.15
	b) Other income	98.55	615.86	147.56	1,138.99
	Total income	9,403.38	10,901.23	7,290.33	38,187.14
2	Expenses				
	a) Cost of materials consumed	4,381.61	4,884.66	2,761.73	16,319.05
	b) Purchases of stock-in-trade	50.91	235.96	159.30	746.83
	c) Changes in inventories of finished goods and work-in-progress	(485.87)	(512.13)	79.86	(614.14)
	d) Employee benefits expenses	1,813.69	1,627.83	1,357.42	6,009.85
	e) Finance costs	364.34	331.03	330.35	1,320.23
	f) Depreciation and amortisation	517.08	490.07	478.98	1,936.74
	g) Other expenses	3,303.84	3,391.27	2,350.98	11,628.56
	Total expenses	9,945.60	10,448.69	7,518.62	37,347.12
3	Profit /(loss) before tax (1-2)	(542.22)	452.54	(228.29)	840.02
4	Tax expense /(credit)				
	Current Tax	-	180.83	-	327.54
	Deferred Tax	(154.67)	(56.50)	(59.10)	(84.04)
	Total tax expense /(credit)	(154.67)	124.33	(59.10)	243.50
5	Net Profit /(loss) after tax (3-4)	(387.55)	328.21	(169.19)	596.52
6	Other comprehensive income /(loss)				
	a) Items that will not be reclassified to profit or loss	(3.46)	43.12	(18.99)	(13.85)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	1.01	(12.56)	5.53	4.03
	Other comprehensive income /(loss) (net of tax)	(2.45)	30.56	(13.46)	(9.82)
7	Total comprehensive income /(loss) (5+6)	(390.00)	358.77	(182.65)	586.70
8	Paid-up equity share capital (face value of Rs. 10/- each)	5,354.90	5,350.03	4,872.58	5,350.03
9	Other equity (revaluation reserve : Rs. Nil)				23,285.18
10	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)				
	Basic	(0.72)	0.67	(0.35)	1.22
	Diluted	(0.72)	0.67	(0.35)	1.22

RB

Notes :

1) The above statement of standalone financial results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 05 August 2026 and 06 August 2026. The above results have been subjected to limited review by Statutory Auditor of the Company.

2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).

3) The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures for the year ended 31 March 2026 and year to date figures upto 31 December 2025, on which auditors had performed a limited review.

4) The Company is principally engaged in a single business segment which is "pharmaceuticals". There is no separate reportable segment as per Ind AS 108 - Operating Segments.

Place: Nagpur
Date: 06 August 2026

Anwar
Siraj Daud

Anwar S. Daud
Managing Director

Digitally signed by Anwar Siraj Daud
DN: cn=Anwar Siraj Daud, postalCode=440002, o=Nagpur,
st=Maharashtra, street=opposite husamya high school
Shanti nagar, Nagpur City M.C, Maharashtra India 440002
Daud compound, title=9918,
2.5.4.20=31623a03c32aeb12337c0f9ed81e7e0f06da09
560707b7e0e0a0e07f0a02,
serialNumber=f0c3342b1c4ef0d7f0c0f0f0e73ebbc5ddc
a313f0e7c0f0f120c0a0e0e0c,
email=Anwar.daud@anwar.in, cn=Anwar Siraj Daud
Date: 2026.08.06 12:03:09 +05'30'

RB